BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

990 related articles for article (PubMed ID: 11587361)

  • 1. Histone deacetylase as a new target for cancer chemotherapy.
    Yoshida M; Furumai R; Nishiyama M; Komatsu Y; Nishino N; Horinouchi S
    Cancer Chemother Pharmacol; 2001 Aug; 48 Suppl 1():S20-6. PubMed ID: 11587361
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potent histone deacetylase inhibitors built from trichostatin A and cyclic tetrapeptide antibiotics including trapoxin.
    Furumai R; Komatsu Y; Nishino N; Khochbin S; Yoshida M; Horinouchi S
    Proc Natl Acad Sci U S A; 2001 Jan; 98(1):87-92. PubMed ID: 11134513
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cyclic hydroxamic-acid-containing peptide 31, a potent synthetic histone deacetylase inhibitor with antitumor activity.
    Komatsu Y; Tomizaki KY; Tsukamoto M; Kato T; Nishino N; Sato S; Yamori T; Tsuruo T; Furumai R; Yoshida M; Horinouchi S; Hayashi H
    Cancer Res; 2001 Jun; 61(11):4459-66. PubMed ID: 11389076
    [TBL] [Abstract][Full Text] [Related]  

  • 4. From discovery to the coming generation of histone deacetylase inhibitors.
    Yoshida M; Matsuyama A; Komatsu Y; Nishino N
    Curr Med Chem; 2003 Nov; 10(22):2351-8. PubMed ID: 14529478
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibitors of histone deacetylase as new anticancer agents.
    Jung M
    Curr Med Chem; 2001 Oct; 8(12):1505-11. PubMed ID: 11562279
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oxamflatin is a novel antitumor compound that inhibits mammalian histone deacetylase.
    Kim YB; Lee KH; Sugita K; Yoshida M; Horinouchi S
    Oncogene; 1999 Apr; 18(15):2461-70. PubMed ID: 10229197
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trichostatin and leptomycin. Inhibition of histone deacetylation and signal-dependent nuclear export.
    Yoshida M; Horinouchi S
    Ann N Y Acad Sci; 1999; 886():23-36. PubMed ID: 10667200
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential response of cancer cells to HDAC inhibitors trichostatin A and depsipeptide.
    Chang J; Varghese DS; Gillam MC; Peyton M; Modi B; Schiltz RL; Girard L; Martinez ED
    Br J Cancer; 2012 Jan; 106(1):116-25. PubMed ID: 22158273
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Deactylase inhibitors disrupt cellular complexes containing protein phosphatases and deacetylases.
    Brush MH; Guardiola A; Connor JH; Yao TP; Shenolikar S
    J Biol Chem; 2004 Feb; 279(9):7685-91. PubMed ID: 14670976
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chlamydocin-hydroxamic acid analogues as histone deacetylase inhibitors.
    Nishino N; Jose B; Shinta R; Kato T; Komatsu Y; Yoshida M
    Bioorg Med Chem; 2004 Nov; 12(22):5777-84. PubMed ID: 15498654
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FR901228, a potent antitumor antibiotic, is a novel histone deacetylase inhibitor.
    Nakajima H; Kim YB; Terano H; Yoshida M; Horinouchi S
    Exp Cell Res; 1998 May; 241(1):126-33. PubMed ID: 9633520
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alkyl-substituted polyaminohydroxamic acids: a novel class of targeted histone deacetylase inhibitors.
    Varghese S; Gupta D; Baran T; Jiemjit A; Gore SD; Casero RA; Woster PM
    J Med Chem; 2005 Oct; 48(20):6350-65. PubMed ID: 16190761
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Amide-based derivatives of β-alanine hydroxamic acid as histone deacetylase inhibitors: attenuation of potency through resonance effects.
    Liao V; Liu T; Codd R
    Bioorg Med Chem Lett; 2012 Oct; 22(19):6200-4. PubMed ID: 22932316
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trichostatin A is a histone deacetylase inhibitor with potent antitumor activity against breast cancer in vivo.
    Vigushin DM; Ali S; Pace PE; Mirsaidi N; Ito K; Adcock I; Coombes RC
    Clin Cancer Res; 2001 Apr; 7(4):971-6. PubMed ID: 11309348
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of novel isoform-selective inhibitors within class I histone deacetylases.
    Hu E; Dul E; Sung CM; Chen Z; Kirkpatrick R; Zhang GF; Johanson K; Liu R; Lago A; Hofmann G; Macarron R; de los Frailes M; Perez P; Krawiec J; Winkler J; Jaye M
    J Pharmacol Exp Ther; 2003 Nov; 307(2):720-8. PubMed ID: 12975486
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Histone deacetylase inhibitors differentially mediate apoptosis in prostate cancer cells.
    Frønsdal K; Saatcioglu F
    Prostate; 2005 Feb; 62(3):299-306. PubMed ID: 15389787
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histone deacetylase inhibitors: molecular and biological activity as a premise to clinical application.
    Santini V; Gozzini A; Ferrari G
    Curr Drug Metab; 2007 May; 8(4):383-93. PubMed ID: 17504226
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of transformed cell growth and induction of cellular differentiation by pyroxamide, an inhibitor of histone deacetylase.
    Butler LM; Webb Y; Agus DB; Higgins B; Tolentino TR; Kutko MC; LaQuaglia MP; Drobnjak M; Cordon-Cardo C; Scher HI; Breslow R; Richon VM; Rifkind RA; Marks PA
    Clin Cancer Res; 2001 Apr; 7(4):962-70. PubMed ID: 11309347
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanism of cell cycle arrest caused by histone deacetylase inhibitors in human carcinoma cells.
    Kim YB; Ki SW; Yoshida M; Horinouchi S
    J Antibiot (Tokyo); 2000 Oct; 53(10):1191-200. PubMed ID: 11132966
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors.
    Finnin MS; Donigian JR; Cohen A; Richon VM; Rifkind RA; Marks PA; Breslow R; Pavletich NP
    Nature; 1999 Sep; 401(6749):188-93. PubMed ID: 10490031
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 50.